Brian Champion
Chief Tech/Sci/R&D Officer bij Akamis Bio Ltd.
Profiel
Brian Champion is currently the Chief Scientific Officer at Akamis Bio Ltd.
He previously held positions as Principal at Celldex Therapeutics, Inc. (Old), GlaxoWellcome, Glaxo, Inc., and Pfizer AB.
He also served as Chief Scientific Officer at Lorantis Ltd.
Actieve functies van Brian Champion
| Bedrijven | Functie | Begin |
|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Brian Champion
| Bedrijven | Functie | Einde |
|---|---|---|
| Pfizer AB | Corporate Officer/Principal | - |
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Corporate Officer/Principal | - |
| Glaxo, Inc. | Corporate Officer/Principal | - |
| GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | - |
Lorantis Ltd.
 Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Chief Tech/Sci/R&D Officer | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Celldex Therapeutics, Inc. (Old)
Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Health Technology |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
| Glaxo, Inc. | |
| Pfizer AB | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
